Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
作者： Jonathan A. Leff , William W. Busse , David Pearlman , Edwin A. Bronsky , James Kemp
DOI: 10.1056/NEJM199807163390302
关键词:
摘要: Background Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control asthma. We evaluated the ability montelukast, leukotriene-receptor antagonist, to protect such patients against bronchoconstriction. Methods randomly assigned 110 (age, 15 45 years) and decrease in forced expiratory volume one second (FEV1) at least 20 percent after exercise on two occasions during placebo run-in period receive 10 mg montelukast (54 patients) or (56 once daily bedtime for 12 weeks double-blind study. Treatment was followed by two-week, single-blind washout which all received placebo. Exercise challenges were performed base line; 24 hours dosing 4, 8, 12; end period. The primary point area under curve FEV1 (expressed as change from base-line values) t...
sci-hub.se 参考文章(19)
P. J. Sterk, L. M. Fabbri, P. H. Quanjer, D. W. Cockcroft, P. M. O'Byrne, S. D. Anderson, E. F. Juniper, J.- L. Malo, Comparison of inspiratory effort in sniff-like aspiration reflex, gasping and normal breathing in cats European Respiratory Journal. ,vol. 6, pp. 53- 59 ,(1993) , 10.1183/09041950.053S1693
H. Croasdell, I. J. M. Doull, S. T. Holgate, N. J. Freezer, Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze European Respiratory Journal. ,vol. 8, pp. 1488- 1493 ,(1995)
M D Inman, P M O'Byrne, The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine. ,vol. 153, pp. 65- 69 ,(1996) , 10.1164/AJRCCM.153.1.8542164
Inge De Lepeleire, Theodore F. Reiss, Felicien Rochette, Albert Botto, Ji Zhang, Sudeep Kundu, Marc Decramer, Montelukast causes prolonged, potent leukotriene D4‐receptor antagonism in the airways of patients with asthma Clinical Pharmacology & Therapeutics. ,vol. 61, pp. 83- 92 ,(1997) , 10.1016/S0009-9236(97)90184-3
Theodore F. Reiss, Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind Trial Archives of Internal Medicine. ,vol. 158, pp. 1213- 1220 ,(1998) , 10.1001/ARCHINTE.158.11.1213
T. R. Jones, M. Labelle, M. Belley, E. Champion, L. Charette, J. Evans, A. W. Ford-Hutchinson, J. -Y. Gauthier, A. Lord, P. Masson, M. McAuliffe, C. S. McFarlane, K. M. Metters, C. Pickett, H. Piechuta, C. Rochette, I. W. Rodger, N. Sawyer, R. N. Yoyng, R. Zamboni, W. M. Abraham, Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D4 receptor antagonist Canadian Journal of Physiology and Pharmacology. ,vol. 73, pp. 191- 201 ,(1995) , 10.1139/Y95-028
Edwin A. Bronsky, James P. Kemp, Ji Zhang, Debra Guerreiro, Theodore F. Reiss, Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clinical Pharmacology & Therapeutics. ,vol. 62, pp. 556- 561 ,(1997) , 10.1016/S0009-9236(97)90051-5
Y KIKAWA, T MIYANOMAE, Y INOUE, M SAITO, A NAKAI, Y SHIGEMATSU, S HOSOI, M SUDO, Urinary leukotriene E4 after exercise challenge in children with asthma. The Journal of Allergy and Clinical Immunology. ,vol. 89, pp. 1111- 1119 ,(1992) , 10.1016/0091-6749(92)90294-C
Rajesh Bhagat, Sanjay Kalra, Veronica A. Swystun, Donald W. Cockcroft, Rapid Onset of Tolerance to the Bronchoprotective Effect of Salmeterol Chest. ,vol. 108, pp. 1235- 1239 ,(1995) , 10.1378/CHEST.108.5.1235
L. Ramage, B.J. Lipworth, C.G. Ingram, I.A. Cree, D.P. Dhillon, Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol Respiratory Medicine. ,vol. 88, pp. 363- 368 ,(1994) , 10.1016/0954-6111(94)90042-6